Key takeaways
- Eli Lilly's Zepbound and Mounjaro sales soared, beating Wall Street estimates and narrowing Novo Nordisk's market share.
- Mounjaro sales surged 91% to $9.94 billion, while weight-loss drug Zepbound brought in $4.93 billion.
- Despite the introduction of oral weight-loss pills, three out of four patients still choose injectable GLP-1 treatments.
- Increased volume and brand competition are driving lower realized prices, shaping a more competitive market for consumers.
Surge in Demand Drives Record Revenues for Eli Lilly
Eli Lilly’s latest quarterly earnings highlight the explosive, resilient consumer demand for its core GLP-1 medications, Zepbound and Mounjaro. According to a report by Reuters, the pharmaceutical giant easily beat Wall Street estimates, raised its full-year revenue outlook, and widened its market lead over Danish competitor Novo Nordisk.
In the reported quarter, Eli Lilly's blockbuster treatments achieved remarkable milestones:
- Mounjaro (approved for type 2 diabetes) saw global sales jump 91% to $9.94 billion.
- Zepbound (approved specifically for weight loss) brought in $4.93 billion, beating analyst estimates of $4.73 billion.
- Together, these two tirzepatide-based drugs accounted for nearly 65% of Eli Lilly’s total quarterly revenue.
By comparison, Novo Nordisk’s competing diabetes and obesity portfolio—led by Ozempic and Wegovy—generated approximately $9.16 billion in quarterly sales. Analysts note that Eli Lilly's strong performance is reassuring to investors, signaling that consumer appetite for injectable GLP-1s remains incredibly high even as new treatment formats, such as oral weight-loss pills, enter the market.
The Battle of Tirzepatide vs. Semaglutide
The financial data underscores a broader trend in the medical weight-loss landscape: a growing preference for tirzepatide (the active ingredient in Zepbound and Mounjaro) over semaglutide (the active ingredient in Wegovy and Ozempic).
As BMO Capital Markets analyst Evan Seigerman told Reuters, the general consensus among many in the medical and investment communities is that "tirzepatide is the better product" because "efficacy is what's key" for consumers. Head-to-head clinical data has historically shown tirzepatide to offer slightly higher average weight loss percentages, which continues to drive brand loyalty and new patient starts. For a detailed breakdown of how these active ingredients compare, read our guide on semaglutide vs. tirzepatide.
To counter this dominance, Novo Nordisk launched an oral pill version of Wegovy in the U.S. earlier this year, bringing in roughly $497 million in its first full quarter. However, this fell slightly below analyst expectations. Eli Lilly executives reported that injectable options still represent about three out of every four new patient starts, proving that patients are highly comfortable with once-weekly injections if they deliver superior clinical results.
Why This Matters for U.S. Consumers Shopping for GLP-1s
For patients looking to navigate the weight-loss market, Eli Lilly's blockbuster financial report has several practical, real-world implications.
1. Pricing Pressures Are Beginning to Benefit Patients
Even though Eli Lilly's overall sales volumes increased, the company noted that its massive revenue gains were partially offset by "lower realized prices." This means that pricing competition between Eli Lilly and Novo Nordisk is intensifying.
Additionally, the rollout of a new Medicare pilot program—which offers eligible patients brand-name weight-loss drugs for a flat $50 monthly co-pay—has stripped away some of the pricing advantages that oral pills initially held over injectables. If you are trying to understand your personal coverage options, check out our resource on what insurance covers GLP-1.
2. Ongoing Supply Strain and the Role of Compounded Alternatives
With global sales of Mounjaro and Zepbound surging, supply chains remain under historical pressure. When brand-name drugs face shortages, many patients turn to compounding pharmacies for access to these therapies. Compounded options can provide a more affordable, accessible path to treatment when commercial insurance denies coverage. To understand the differences in safety, regulation, and manufacturing, read our analysis of compounded vs. brand-name semaglutide.
3. Telehealth Providers Make Access Seamless
The soaring demand highlighted in Eli Lilly's earnings report has been met by a rapid expansion of online healthcare platforms. Telehealth clinics have made it easier than ever for patients to consult with licensed U.S. providers, obtain prescriptions, and secure insurance prior authorizations from home.
If you are ready to explore your options, you can use our questionnaire to find a program tailored to your budget and clinical goals. To compare top-rated online clinics side-by-side on pricing, medication availability, and support services, visit our compare providers page.
Disclaimer: CompareRx does not provide medical advice. Always consult with a licensed healthcare professional before starting any weight-loss medication or treatment plan.